Medical News

RSS

New series of single output power supplies from ICC

International Components Corporation (ICC), an established global leader in designing and manufacturing portable rechargeable systems, today launched a new series of high-efficiency AC-DC open-frame, single output power supplies marketed under the Elpac Power Systems(TM) brand name.

19 Oct 2009

Vaccinations and preventative hygiene routines can help protect families from H1N1

According to the Centers for Disease Control and Prevention (CDC), 37 states in the U.S. now report widespread influenza activity - and nearly all influenza cases reported to the health authority are 2009 H1N1, also known as swine flu. However, with the release of a 2009 H1N1 vaccine this week, parents have a new preventative tool to help keep their families safe from illness.

19 Oct 2009

Hansen Medical announces its plan to restate its previous financial results

Hansen Medical, Inc. today announced that it plans to restate its financial statements for the year ended December 31, 2008 and for the quarters ended March 31, 2008, June 30, 2008, September 30, 2008, March 31, 2009 and June 30, 2009 in order to correct certain errors, some of which arose from potential irregularities occurring outside of the accounting department, regarding the timing of revenue recognition on the sale of some of its Sensei® Robotic Catheter Systems.

19 Oct 2009

FDA approves Quotient Biodiagnostics' BLA for transfusion diagnostic monoclonal antibodies

Quotient Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. These products are for use by blood donor centers, reference laboratories, and hospitals to type and screen blood.

19 Oct 2009

GenoLogics and CLC bio to provide end-to-end informatics solution for workflow management

GenoLogics and CLC bio today announced they will provide an end-to-end informatics and analysis solution, optimized for Next Generation Sequencing research that addresses both lab and data management and data analysis all within one integrated system.

19 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.

19 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Sonosite resolves all pending patent litigation with General Electric

SonoSite, Inc., the world leader and specialist in hand-carried ultrasound for the point-of-care, announced today that the company has resolved all pending patent litigation with General Electric Company (GE).

19 Oct 2009

Campaign to educate men and women about fibromyalgia

Women and men have opposing views on many topics, and it turns out that they also have different takes on chronic pain.

19 Oct 2009

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

19 Oct 2009

Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis

Emisphere Technologies, Inc. announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis.

19 Oct 2009

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Arigene to purchase all outstanding shares of common stock of Trimeris

Arigene Co., Ltd., a Korean corporation traded on the Korean Securities Dealers Association Quotation System, through its wholly-owned subsidiary, RTM Acquisition Company, a Delaware corporation, today commenced a cash tender offer to purchase all outstanding shares of common stock of Trimeris, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger among Arigene, RTM Acquisition Company and Trimeris, executed and publicly announced on October 2, 2009.

19 Oct 2009

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

ChemDiv, Inc. of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Premier Plastic Surgery of Kansas City, serving residents of Kansas City and beyond for 22 years, has redesigned its extensive website to include a separate section on Cosmetic Surgery for Males, a new Skin Care Centre, and a Plastic Surgery Blog that features breaking news on emerging research, techniques and products.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Medical News

New series of single output power supplies from ICC

Vaccinations and preventative hygiene routines can help protect families from H1N1

Hansen Medical announces its plan to restate its previous financial results

FDA approves Quotient Biodiagnostics' BLA for transfusion diagnostic monoclonal antibodies

GenoLogics and CLC bio to provide end-to-end informatics solution for workflow management

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

Metabolic master switch sets the biological clock in body tissues

Sonosite resolves all pending patent litigation with General Electric

Campaign to educate men and women about fibromyalgia

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Arigene to purchase all outstanding shares of common stock of Trimeris

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

Chinese SFDA approves China Medical Technologies' SPR System

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Latest News